Month: April 2026

SAN DIEGO and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “Arrangement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“Hanmi Purchaser” and together with Hanmi, the “Hanmi Purchasers”), has been delayed as certain Korean regulatory approvals pertaining to the Arrangement remain in progress. The parties do not anticipate that the review will prevent closing and continue to work toward completing the Arrangement that they now target for the month of May. The Company will provide a further update when available. Transaction Details As previously disclosed in the Company’s news release dated November 19, 2025 (here), upon the...

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 7, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company’s website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921...

RENO, Nev., April 30, 2026 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in energy storage and maker of Battle Born Batteries®, today announced that the Company will release its financial and operational results for the first quarter ended March 31, 2026 after market close on Thursday, May 14, 2026. The earnings press release will be followed by a conference call on Thursday, May 14, 2026, at 4:30 PM Eastern Time. Interested investors and other parties may access the live webcast via the link found here or through the Events and Presentations page within the Investor Relations section of Dragonfly Energy’s website at https://investors.dragonflyenergy.com/events-and-presentations/default.aspx. The conference call can also be accessed by dialing (833) 461-5787...

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closing Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended March 31, 2026, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance...

MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) pharmaceutical company, will release its first quarter 2026 financial results on Thursday, May 7, 2026 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, May 7, 2026 Time: 8:30 a.m. ET Telephone: Toll Free: 1-888-699-1199 or International 1-416-945-7677 Webcast: www.knighttx.com or WebcastThis is a listen-only audio webcast. Media Player is required to listen to the broadcast. Replay: An archived replay will be available for 30 days at www.knighttx.com. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused...

Company Increases Full-Year 2026 Adjusted Earnings Per Share Guidance MIAMI, April 30, 2026 (GLOBE NEWSWIRE) — Laureate Education, Inc. (NASDAQ: LAUR), which operates five higher education institutions across Mexico and Peru, today announced financial results for the first quarter of 2026. First Quarter 2026 Highlights (compared to first quarter 2025):New enrollments increased 9%. Total enrollments increased 6%. On a reported basis, revenue increased 15% to $272.6 million. On a constant currency basis1, revenue increased 1% and was unfavorably affected by approximately $9 million of intra-year academic calendar timing attributable to later semester start dates in the first quarter of 2026 as compared to the first quarter of 2025. Operating loss for the first quarter of 2026 was $(27.5) million, compared to an operating loss of...

Shelton, CT, April 30, 2026 (GLOBE NEWSWIRE) — HUBBELL REPORTS FIRST QUARTER 2026 RESULTS Q1 diluted EPS of $3.41; adjusted diluted EPS of $3.93 (up 16% y/y) Q1 net sales 11% (organic 8.2%; foreign exchange 0.6%; M&A 2.3%) Q1 operating margin 17.4%; adjusted operating margin 19.8% (up 110 bps y/y) Raising FY 2026 diluted EPS expected range to $17.45-$18.00; adj. diluted EPS of $19.30-$19.85SHELTON, CT. (April 30, 2026) – Hubbell Incorporated (NYSE: HUBB) today reported operating results for the first quarter ended March 31, 2026. “Hubbell delivered strong performance in the first quarter, with double digit growth in sales, operating profit and earnings per share” said Gerben Bakker, Chairman, President and CEO. Mr. Bakker continued, “Organic sales growth of 8% in the first quarter was driven by double...

MARA to purchase Long Ridge for total transaction value of approximately $1.52 billion FIP plans to use net proceeds to repay corporate debt and reinvest in growth opportunities Transaction expected to close in the third quarter of 2026 following receipt of necessary regulatory approvals NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) — FTAI Infrastructure Inc. (NASDAQ:FIP; the “Company” or “FIP”) announced today that it has entered into a definitive agreement to sell Long Ridge Energy & Power LLC (“Long Ridge”) and certain related assets to a subsidiary of MARA Holdings, Inc. (NASDAQ: MARA). The transaction is valued at approximately $1.52 billion before closing adjustments. Headquartered in Pittsburgh, Pennsylvania, Long Ridge is a vertically integrated power and gas company comprised of a highly efficient, 485-megawatt...

– Q4 revenue surpasses $5 million threshold – –Company to host conference call today, April 30th  at 11am ET/8am PT – NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., April 30, 2026 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. All figures are in U.S. dollars. Financial and Business HighlightsFirst $5 million quarter – Q4 2025 sales were $5,022,865 compared to $4,430,755 in Q3 2025 and $4,702,317 in Q4 2024.Strong improvements in EBITDAC – EBITDAC for FY2025 was $587,532 compared to $282,450 in 2024, an improvement of 108% or $305,082. EBITDAC...

~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~ ~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential Phase III design and analysis plan for AMT-130 four-year data ~ ~ uniQure actively pursuing additional ex-US regulatory pathways to support potential registration of AMT-130 in international markets ~ LEXINGTON, Mass. and AMSTERDAM, April 30, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the Company held a Pre-Submission Meeting with the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA) and plans to submit a Marketing Authorization Application (MAA) for AMT-130 for the treatment...